- Trade options, futures, options on futures, stocks, ETFs
- $0 commission to close options
- Pro-grade platform and risk analysis tools
Finder makes money from featured partners, but editorial opinions are our own.
Advertiser disclosure
BridgeBio Pharma is a biotechnology business based in the US. BridgeBio Pharma shares (BBIO) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $26.21 – a decrease of 4.66% over the previous week. BridgeBio Pharma employs 550 staff and has a trailing 12-month revenue of around $217.8 million.
Our top picks for where to buy BridgeBio Pharma stock
- Trade $0 commission stocks & ETFs with as little as $1
- Earn up to $300 with qualifying deposits
- Discover new opportunities with Opto's AI-driven thematic investing system
- Theme and ETF screener
- Trade stocks, options, ETFs, mutual funds, alternative asset funds
- $0 commission on stocks, ETFs and options with no options contract fees
- Get up to $1,000 in stock when you fund a new account within 30 days
- Complimentary access to a financial planner
Probability of member receiving $1,000 is 0.028%
How to buy BridgeBio Pharma stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – BBIO. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy BridgeBio Pharma stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.1 - 4 of 4
What is the Finder Score?
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
BridgeBio Pharma stock price (NASDAQ: BBIO)
Use our graph to track the performance of BBIO stocks over time.BridgeBio Pharma shares at a glance
Information last updated 2024-12-19.
| Latest market close | $26.21 |
|---|---|
| 52-week range | $21.62 - $44.32 |
| 50-day moving average | $25.65 |
| 200-day moving average | $26.67 |
| Wall St. target price | $48.53 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-2.42 |
Is it a good time to buy BridgeBio Pharma stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
BridgeBio Pharma price performance over time
Historical closes compared with the close of $25.98 from 2024-12-18
| 1 week (2024-12-13) | -5.49% |
|---|---|
| 1 month (2024-11-20) | 12.76% |
| 3 months (2024-09-20) | -2.84% |
| 6 months (2024-06-20) | -3.96% |
| 1 year (2023-12-20) | -31.99% |
|---|---|
| 2 years (2022-12-20) | 214.53% |
| 3 years (2021-12-20) | 41.44 |
| 5 years (2019-12-20) | 41.54 |
BridgeBio Pharma financials
| Revenue TTM | $217.8 million |
|---|---|
| Gross profit TTM | $74.2 million |
| Return on assets TTM | -48.88% |
| Return on equity TTM | -1789.67% |
| Profit margin | -201.53% |
| Book value | $-6.51 |
| Market Capitalization | $4.9 billion |
TTM: trailing 12 months
BridgeBio Pharma share dividends
We're not expecting BridgeBio Pharma to pay a dividend over the next 12 months.
BridgeBio Pharma share price volatility
Over the last 12 months, BridgeBio Pharma's shares have ranged in value from as little as $21.62 up to $44.32. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while BridgeBio Pharma's is 1.086. This would suggest that BridgeBio Pharma's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
BridgeBio Pharma overview
BridgeBio Pharma, Inc. , a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc.
Frequently asked questions
What percentage of BridgeBio Pharma is owned by insiders or institutions?Currently 5.422% of BridgeBio Pharma shares are held by insiders and 94.137% by institutions. How many people work for BridgeBio Pharma?
Latest data suggests 550 work at BridgeBio Pharma. When does the fiscal year end for BridgeBio Pharma?
BridgeBio Pharma's fiscal year ends in December. Where is BridgeBio Pharma based?
BridgeBio Pharma's address is: 3160 Porter Drive, Palo Alto, CA, United States, 94304 What is BridgeBio Pharma's ISIN number?
BridgeBio Pharma's international securities identification number is: US10806X1028 What is BridgeBio Pharma's CUSIP number?
BridgeBio Pharma's Committee on Uniform Securities Identification Procedures number is: 10806X102
More resources on Finder
More guides on Finder
-
How to buy Merck-and-Company stock (MRK)
Steps to owning and managing MRK, with 24-hour and historical pricing before you buy.
-
How to buy Eli Lilly and Company stock (LLY)
Steps to owning and managing LLY, with 24-hour and historical pricing before you buy.
-
How to buy Intuitive Surgical stock (ISRG)
Steps to owning and managing ISRG, with 24-hour and historical pricing before you buy.
-
How to buy Vertex Pharmaceuticals stock (VRTX)
Steps to owning and managing VRTX, with 24-hour and historical pricing before you buy.
-
How to buy McKesson Corporation stock (MCK)
Steps to owning and managing MCK, with 24-hour and historical pricing before you buy.
-
How to buy UnitedHealth Group Incorporated stock (UNH)
Steps to owning and managing UNH, with 24-hour and historical pricing before you buy.
-
How to buy Amgen stock (AMGN)
Steps to owning and managing AMGN, with 24-hour and historical pricing before you buy.
-
How to buy Abbott Laboratories stock (ABT)
Steps to owning and managing ABT, with 24-hour and historical pricing before you buy.
-
How to buy Pfizer stock (PFE)
Steps to owning and managing PFE, with 24-hour and historical pricing before you buy.
-
How to buy Johnson & Johnson stock (JNJ)
Steps to owning and managing JNJ, with 24-hour and historical pricing before you buy.
Ask a question